The management of infections due to Klebsiella pneumoniae has been complicated by the emergence of antimicrobial resistance, especially to the carbapenems. Resistance to the carbapenems in K. pneumoniae involves multiple mechanisms, including the production of carbapenemases (e.g. KPC, NDM, VIM, OXA-48-like), as well as alterations in outer membrane permeability mediated by the loss of porins, and the up regulation of efflux systems. The latter two mechanisms are often combined with high levels of other types of β-lactamases (e.g. 1 AmpC). K. pneumonaie ST258 emerged during the early to mid-2000s as important human pathogens and has spread extensively throughout the world. ST258 comprises of 2 distinct lineages namely clade I and clade II and it seems that ST258 is a hybrid clone that was created by a large recombination event between ST11 and ST442. Incompatiblity group F plasmids with bla KPC have contributed significantly to the success of ST258. The optimal treatment of infections due to carbapenemase-producing K. pneumoniae remains unknown. Some newer agents show promise for treating infections due to KPC-producers, however effective options for the treatment of NDM-producers remain elusive.
Introduction
The genus Klebsiella spp. belongs to the family Enterobacteriaceae that include saprophytes often isolated from the environment. Klebsiella pneumoniae is the most clinically relevant Klebsiella species and is responsible for over 70% of human infections due to this genus (1) . In humans, K. pneumoniae most often colonizes the gastrointestinal tract, skin, and nasopharynx and is an important cause of serious community-onset infections such as necrotizing pneumonia, pyogenic liver abscesses, endogenous endophthalmitis (2, 3) . During the 1970's, K. pneumoniae became an important cause of nosocomial infections, especially urinary tract infections (UTIs), respiratory tract infections and bloodstream-associated infections (BSIs) (1, 2, 4) . A recent report from the CANWARD surveillance program showed that K. pneumoniae Greece (some isolates with VIMs have MICs to imipenem lower than 0.5 µg/ml) (29) . It is possible that the initial spread of K. pneumoniae with carbapenemases was due to isolates with low MICs to the carbapenems without permeability modifications.
Genetic supports of carbapenemase genes
The different carbapenemase genes circulating within K. pneumoniae are often carried by mobile structures including plasmids and transposons and therefore can spread efficiently to different members of the Enterobacteriaeacae. Transposon Tn4401 has been shown to be the main genetic structures enhancing the spread of bla KPC -type genes onto different plasmid scaffolds, but its transposition is not very efficient and the frequency of transmission has been quantified at 4.4 x 10 -6 (30, 31 
Clonal complex (CC) 258: ST258
The rate and consequence with which carbapenem resistance had disseminated globally in K. pneumoniae had raised cause for alarm among the medical community at large. To date, bla KPC has been found in more than 100 different sequence types (STs), but this pandemic is primarily driven by the spread of KPC-producing K. pneumoniae isolates that are members of clonal complex (CC) 258 (18) . CC258 (founder member is ST292) consists of one predominant ST namely ST258, and to a lesser extent ST11, ST340 and ST512 that are single locus variants (SLVs) of ST258 (18, 32) . K. pneumoniae ST258 is a prototype of a high risk clone and recent information about the epidemiology, genetic rearrangement and evolution of this successful clone had provided insights into the global spread of antimicrobial drug resistance. 
The importance of epidemic plasmids in spreading carbapenemase genes
Plasmids are extra chromosomal elements of double stranded DNA present in bacteria, which replicate independently of the host genome (73) . Plasmids can undergo horizontal transfer through conjugation thereby transferring the encoded genetic elements from one bacterium to
another. This movement of plasmid-borne antibiotic resistance genes has been central to the recent and rapid increase in global antimicrobial resistance (17) . DNA on plasmids used for replication purposes needs to be conserved and therefore is utilized for the classification of plasmids. This "incompatibility group typing" scheme is based on unique replication areas identified in different plasmids to demonstrate relatedness and behavior of particular plasmids groups (74, 75) . Antimicrobial resistance plasmids can broadly be divided into two main groups namely the narrow-host range group that most often belongs to the incompatibility (Inc) group F and the broad-host range group that belongs to the IncA/C and IncN. They have recently been termed "epidemic resistance plasmids" due to their propensity to acquire resistance genes and rapid dissemination among Enterobacteriaceae (76) . Antimicrobial resistance determinants on epidemic plasmids provide a selective advantage to high risk clones and are likely central to their success (77, 78) .
Plasmids associated with K. pneumoniae ST258 with bla KPC
Several different KPC-containing plasmids have been identified in ST258. They belong to IncF (with FIIk1, FIIk2, and FIA replicons), IncI2, IncX, IncA/C, IncR, and ColE1 and these plasmids often contain various genes encoding for non-susceptibility to different antimicrobial drugs (32) . However, the most predominant bla KPC -plasmid types associated with K. (81, 82) . This suggests that ST258
with bla KPC-3 on KpQIL plasmids were introduced during the mid-2000s from the USA into Israel (a Founder effect) followed by clonal expansion in Israel. The IncFIIk plasmids are also the most common plasmid identified among ST258 with bla KPC from several different geographically diverse areas including Canada, Poland, United States, Israel, Brazil, Italy, and Norway (51, 79, 83) . There also appears to be an association between different plasmid Inc groups and the ST258 clades I and II. The bla KPC-3 -associated IncI2 plasmids and bla KPC-3 -associated IncFIA plasmids were found exclusively in clade II while the pKpQIL-associated
IncFIIk2 plasmids with bla KPC-2 were detected in both clades I and II (55) . pKpQIL plasmids were not only restricted to ST258 and were present in 33% of non-ST258 K. pneumoniae in the New York area (81).
The complete sequencing of plasmids associated with ST258 from large collections are revealing that they are evolving over time through large genetic rearrangements (79, 84, 85 By contrast to what has been observed with bla NDM genes, the current emergence of OXA-48-producing isolates in many geographical areas is mainly explained by the success of one specific plasmid (pOXA-48a). This plasmid is 62-kb in-size and belongs to the IncL/M incompatibility group (34) . Noteworthy, it possesses bla OXA-48 as a unique antibiotic resistance gene, in contrast again with bla NDM -positive plasmids that often contain several antibiotic resistance genes. Plasmid pOXA-48a is self-conjugative and it has been demonstrated that its tir gene, known to encode a transfer inhibition protein, was truncated. This inactivation was shown to be responsible for a 50-to 100-fold increase in the efficiency of transfer of pOXA-48a, and therefore explains the very high conjugation rate of that latter plasmid which was estimated to be around 1 x 10 -1 (35) . Therefore, it is considered that these specific features of plasmid pOXA48a do explain in large part the current spread of the OXA-48 encoding gene.
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The success and virulence factors of K. pneumoniae ST258 K. pneumoniae is responsible for human and animal infections and has also been implicated in causing diseases in certain plants such as spinach, rice and pineapples (93) . It remains unclear how one bacterium are successful in causing infections in plants and human. K.
pneumoniae also has the ability to survive from long periods in the hospital environment (83) .
Recently Lerner and colleagues identified super-spreaders among carbapenemase-producing K.
pneumoniae isolated from rectal and environmental specimens (94) . These super-spreaders were more likely to have high rectal concentrations and more likely to have high concentrations in the immediate environment may play a central role in transmission of carbapenemase-producing K.
pneumoniae. Reservoirs in the patient or health care worker populations and the environment represent principle modes of spread in nosocomial outbreaks with the patient population being the most important reservoir in high-frequent outbreaks (83, 94) .
The global molecular epidemiology of KPC-producing bacteria shows that K.
pneumoniae is the most common species and ST258 is the predominant clone, suggesting a unique fitness and selective advantage beyond merely antimicrobial resistance. The reasons for the particular success of ST258 and its association with certain resistance plasmids are uncertain.
However, its ability to spread swiftly is beyond dispute.
It is unclear if ST258 has increased virulence when compared to other K. pneumoniae
isolates. A recent study demonstrated that ST258 is non-virulent in animal models, highly susceptible to serum killing and rapidly undergoing phagocytosis (95) . Another study showed that not all ST258 behaved the same in a mouse lethality model but consistency did exist in a moth (Galleria mellonella) virulence model (96) . ST258 also lacks well-characterized K.
pneumoniae virulence factors, including K1, K2, and K5 capsular antigen genes, the aerobactin genes, and regulator of mucoid phenotype gene rmpA (95 So far no specific virulence factor has been identified in those widespread clones producing NDM-or OXA-48-type enzymes, the main driving factor of those disseminated clones apparently being resistance to antibiotics only.
Treatment of infections due to K. pneumoniae with carbapenemases
Infections due to K. pneumoniae with carbapenemases often reach mortality rates ranging between 23 and 75%, which is attributed to the lack of active antimicrobial agents and underlying co-morbidities in patients (101) . A delay in the appropriate antibiotic therapy for severe infections is strongly associated with impaired outcome and increased mortality for patients with severe sepsis and septic shock and is also relevant for patients with infections due to K. pneumoniae with carbapenemases (101). The optimal treatment of infections due to carbapenemase-producing K. pneumoniae is unknown and none of the currently available antibiotics used as single therapy may be effective for treating infections with all types of carbapenemase producers. Source control in addition to antimicrobial therapy, is essential for the effective management of these infections and is especially significant for the successful treatment of urinary tract and intra-abdominal infections. Empirical combination therapy including colistin, carbapenem or aminoglycoside, based on the local resistance epidemiology, might be justified for severely ill patients with suspected infection due to K. pneumoniae with carbapenemases (102).
Most clinical data on the efficacy of antibiotics for treating carbapenemase producers are from retrospective case series and anectodal case reports and mostly due to KPC-producing K.
pneumoniae (103, 104 (14) . Combined mechanisms of resistance to ß-lactams are often observed among the carbapenemase-producing K. pneumoniae (22, 25, 37).
Combined therapy may maximize bacterial killing (synergistic effect) and minimize bacterial resistance. The best antibiotic associations contain two molecules that show in-vitro activities against carbapenemase producers (103, 106) . Several studies indicated that mortality was significantly lower in patients when given combination therapy (106, 107) while other studies indicated that the superiority of the combined therapy as compared to monotherapy was 20 not significant (103) . A recent review article recommends using combination therapy for treating bloodstream infections when multidrug-resistant bacteria are suspected (108) . Doi and Paterson, based on an extended analysis of the in-vivo efficacy data, recommend combination therapy that includes a carbapenem with the second agent such as colistin, tigecylcine and gentamicin depending of the results of in-vitro susceptibility testing (109) .
Options for the treatment of infections with carbapenemase-producing K. pneumoniae are limited. Some studies suggest that for infections due to KPC producers, the use of combination therapy that includes a carbapenem (eg, polymyxin-carbapenem or aminoglycosidecarbapenem), may have a mortality benefit (101) . Clinical data are scant for treatment of infections due to OXA-48 and NDM infections; a recent retrospective, observational study suggested that for bacteremia from OXA-48 producers, combination therapy that included colistin showed a mortality benefit (110).
Colistin (polymyxin E) was discovered more than 60 years ago while polymyxin B is available only in a limited number of countries. The major side effect of these molecules is nephrotoxicity, while the optimal dosage is unknown. Colistin has become the most popular agent for the treatment of infections due to K. pneumoniae with carbapenemases (101, 102) .
Colistin monotherapy has been associated with mortality rates exceeding 50% when used for severe infections (111) and one Brazilian study shows that combination therapy was not superior to monotherapy (112) . Recent understanding of the pharmacokinetics of colistin has resulted in the use of higher doses than those used in the early studies. The current recommendations include a loading dose and a total standard dose of 9-10 million international units daily divided into two or three doses (113) . This molecule has significant activity against various carbapenemase-producing isolates and is often used in combined therapy (e.g. aminoglycoside,
aztreonam, carbapenems, rifampicin, tigecycline or fosfomycin) (103, 104) . Unfortunately, due to the increase use of this agent, colistin-resistant K pneumonaie are increasingly being reported (114) .
Intravenous Fosfomycin is available in Europe where it has been used in combination with other antibiotics for treating severe infections due to multiple drug resistant bacteria (with tigecycline and colistin) (115) . In-vitro analysis indicated synergies between colistin and fosfomycin for some NDM producers (116) .
Tigecycline is a tetracycline derivative and has been available since 2005. This molecule does not diffuse sufficiently into the urinary tract where many of the infections due to carbapenemase-producing K. pneumoniae originate (104) . The FDA issued in 2013 a warning indicating an increase rate of death when tigecycline has been used (2.5%) when compared with other antibiotics (1.8%) that were related to treatment failures (104) . In addition, acquired tigecycline resistance has been reported in patients infected by KPC-producing K. pneumoniae (117) . A recent report suggest that high dose tigecycline (100 mg every 12 hours following a 200 mg loading dose) may improve outcome when compared to conventional doses (118) .
Rifampicin has a very broad spectrum of activity including the Enterobacteriaceae.
Several reports show some in vitro synergy in the killing of carbapenemase-producing K.
pneumoniae between rifampicin and tigecycline or colistin (119, 120) . However definitive clinical data are lacking to advocate the routine use of rifampicin for the treatment of infections due to carbapenemase-producing K. pneumoniae.
Several aminoglycosides molecules may retain activity against carbapenemase producing K. pneumoniae. Some KPC and OXA-48 producers remain susceptible to gentamicin while this is rare for NDM producers (121) . Aminoglycosides have been used with some clinical success either alone or in combined therapy for treating infections due to KPC producers (106) . A recent report suggested better outcomes when gentamycin (as monotherapy or in combination with tigecycline) was used for colistin-resistant, KPC-producing K. pneumoniae (122) . Side effects of aminoglycosides include nephrotoxicity especially when used in combination with colistin.
The carbapenems, despite being hydrolyzed by carbapenemases (hence the definition of those enzymes) may retain some activity against carbapenemase-producing K. pneumoniae (106, 123) . Treatment regimens using a carbapenems may be an option when the MICs of the carbapenems are below or equal to 8 mg/L when a second antibiotic is added or when prolonged intravenous infusion regimen is given (123, 124) . Encouraging results with VIM and OXA-48
producers in humans and with NDM producers in animal models had been obtained (106, 125, 126) . Studies performed with an animal model of infection (i.e. pneumonia model in mice)
suggested that dual-carbapenem therapy (i.e. meropenem + ertapenem) may be effective (126) .
Ertapenem most likely acts as a "suicide" molecule for carbapenemase activity whereas the more active drug, meropenem retains its efficacy. Efficacy of this double-carbapenem therapy has been shown in humans infected with KPC producers (127) . Among other ß-lactams, the extended-spectrum cephalosporins (i.e. 3 rd and 4 th generation) may be effective against OXA-48 producers without ESBLs (128) while aztreonam remains an option for treating infections due to MBL producers that test susceptible to this agent (37).
Several antibiotics in development may have significant activity against carbapenemase producers in K. pneumoniae (104) . Within the next 24 months, is likely that the combination of avibactam and ceftazidime will be available in clinical medicine and may represent an important additional value for treating the increasing number of difficult-to-treat infections due to carbapenemase producers.
Implementation of hygiene measures, rapid detection of carbapenemase producers and the use of the combination of avibactam and ceftazidime might be the cornerstones to treat and control infections due to K. pneumoniae with KPCs or OXA-48. However, the efficient treatment of MBL producers (i.e. VIM, IMP and NDM) will remain to be determined.
Recent recommendations
Rodríguez-Baño and colleagues from Spain (102) and Giamarellou (101) from Greece recently published excellent recommendations regarding the treatment of infections with carbapenemase-producing Enterobacteriaceae. These recommendations or guidelines contained pertinent and detailed information on this important topic and we urged interested readers to securitize these articles.
Summary
The management of infections due to K. pneumoniae has been complicated by the emergence of antimicrobial resistance. Of special concern is the emerging resistance to the Diseases (133) . Colonized or infected patients should be isolated individually or in groups and treated in accordance with strict infection control directives, including hand disinfection, use of gowns and disposable aprons as well as proper cleaning (111) .
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